All In Biotech

Free tool

FAERS Monitor: Daurismo

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210656 or its brand name (Daurismo, Glasdegib Maleate). Reports on generic versions are filed under their own applications.

Reports

474

Serious

443

93% of reports

Hospitalization

227

Death reported

193

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death111
  • febrile neutropenia69
  • pneumonia48
  • off label use34
  • neoplasm progression28
  • neutropenia24
  • sepsis15
  • toxicity to various agents13
  • electrocardiogram qt prolonged12
  • product use in unapproved indication11
  • septic shock11
  • decreased appetite10
  • drug ineffective10
  • infection10
  • pyrexia10

Reports by year received

View as table
YearReports
20131
20151
20163
201813
2019116
2020121
2021107
202245
202320
202422
202517
20268

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,685 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
febrile neutropeniaSignal6946.237.13,013
neoplasm progressionSignal2835.825.0913
electrocardiogram qt prolongedSignal1214.88.5141
septic shockSignal1111.26.393
neutropeniaSignal247.85.3137
pneumoniaSignal486.65.0225
sepsisSignal156.03.657
deathSignal1115.74.9446
toxicity to various agentsSignal133.42.020
infectionSignal103.11.712
product use in unapproved indication112.01.14
decreased appetite101.91.04
off label use341.71.210
pyrexia101.30.70
drug ineffective100.30.213

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.